Hermann P, Rodger S D, Remones G, Thenot J P, London D R, Morselli P L
Eur J Clin Pharmacol. 1983;24(3):349-52. doi: 10.1007/BF00610053.
The kinetic profile of diltiazem, a novel calcium antagonist, was studied in 12 volunteers following oral (60 mg) and intravenous (15 mg) administration. After i.v. administration biphasic elimination was observed, with a distribution half-life of 0.3 +/- 0.2 h and an elimination half-life of 3.1 +/- 1.0 h; the apparent volume of distribution was 5.3 +/- 1.71/kg and the total clearance was 1.28 +/- 0.48 l/kg/h. After the oral dose the elimination had a half-life of 3.2 +/- 1.3 h. The absolute bioavailability of diltiazem ranged from 24 to 74% (mean 42 +/- 18%). The interindividual variation may be explained by a variable first pass effect.
在12名志愿者口服(60毫克)和静脉注射(15毫克)后,对新型钙拮抗剂地尔硫䓬的动力学特征进行了研究。静脉注射后观察到双相消除,分布半衰期为0.3±0.2小时,消除半衰期为3.1±1.0小时;表观分布容积为5.3±1.71升/千克,总清除率为1.28±0.48升/千克/小时。口服给药后消除半衰期为3.2±1.3小时。地尔硫䓬的绝对生物利用度在24%至74%之间(平均42±18%)。个体间差异可能由首过效应的变化来解释。